Piramal Pharma Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.

Results View source PDF Explain this filing

PPLPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.2%Reaction day

₹155.00

prior close

₹150.00

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-0.1%-1.1% vs market

Pharmaceuticals peers, median of 158sector-0.6%-0.6% vs sector

On the reaction day the stock moved 1.1 pts less than Nifty Smallcap 250 and 0.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.7

10m

+2.7

15m

+2.9

30m

+3.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.2-0.1-1.1-0.6-0.6

Next day

-0.2+0.8-1.0+0.7-0.9

+0.6-0.8+1.5-0.2+0.8

+3.9+2.1+1.9+2.4+1.5

+4.3+2.8+1.4+2.9+1.3

+2.4+1.8+0.6+2.2+0.2

+4.9+4.0+0.9+3.1+1.8

15d

+4.5+2.2+2.3+1.2+3.3

-1.3-0.4-0.9-2.0+0.7

-11.8-8.6-3.2-12.9+1.1

+3.6+7.4-3.9+3.3+0.3

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 158Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Piramal Pharma Limited has filed its financial results for the quarter and nine months ended December 31, 2025 with the stock exchange. The announcement is only a compliance filing confirming that results have been submitted, and does not include the actual numbers or a press release. Investors will need to refer to the detailed results PDF filed separately for revenue, profit, and segment performance. No management commentary or guidance is included in this filing.

Likely market impact

Neutral on its own — this is a routine regulatory disclosure. Stock reaction will depend entirely on the actual numbers in the results PDF, which are not part of this announcement.